Keywords
Asthma ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

295 Search results.

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 - Eligibility

- 5/22/15 - 1 form, 2 itemgroups, 27 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00640016

Effect of one week repeat dosing of GW685698X and FP on serum cortisol (103096) - Eligibility Question

- 1/12/21 - 1 form, 4 itemgroups, 26 items, 1 language
Itemgroups: Administrative, Eligibility Question, Inclusion Criteria, Exclusion Criteria
Study ID: 103096 Clinical Study ID: 103096 Study Title: A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of GW685698X and FP on twenty-four hour serum cortisol in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Fluticasone Furoate;Fluticasone Propionate Trade Name: Fluticasone Furoate;Fluticasone Propionate Study Indication: Asthma

Eligibility Collection of Clinical Data That Will be Used in This Study and Will Form a Data Bank for Asthma in Saudi Arabia NCT01216215

- 6/13/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia; ODM derived from: https://clinicaltrials.gov/show/NCT01216215

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Administrative and Demography Form

- 4/30/20 - 1 form, 5 itemgroups, 15 items, 1 language
Itemgroups: Inform Screening, Inform Enrollment, Date of Visit/ Assessment, Subject Identification, Demography Data
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Eligibility Intrinsic Asthma NCT01144910

- 4/23/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children; ODM derived from: https://clinicaltrials.gov/show/NCT01144910

Eligibility Eosinophilic Asthma NCT01290887

- 12/13/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01290887

Eligibility Difficult Asthma NCT01862289

- 11/23/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prevalence of Hyperventilation Syndrome in Difficult Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01862289

Eligibility Bronchial Asthma NCT01414868

- 10/21/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA); ODM derived from: https://clinicaltrials.gov/show/NCT01414868

Eligibility Bronchial Asthma NCT01386151

- 10/21/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01386151

Eligibility Bronchial Asthma NCT01618929

- 10/21/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Montelukast in Asthmatic Children With and Without Food Allergy; ODM derived from: https://clinicaltrials.gov/show/NCT01618929

Eligibility Bronchial Asthma NCT01455194

- 10/21/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of High Dose Ciclesonide on Asthma Control; ODM derived from: https://clinicaltrials.gov/show/NCT01455194

Eligibility Bronchial Asthma NCT01113437

- 10/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Omalizumab in Non-atopic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01113437